Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction

Author:

Lopes Renato D.1ORCID,Alexander Karen P.2,Stevens Susanna R.2,Reynolds Harmony R.3ORCID,Stone Gregg W.4,Piña Ileana L.5,Rockhold Frank W.2ORCID,Elghamaz Ahmed6,Lopez-Sendon Jose Luis7,Farsky Pedro S.8ORCID,Chernyavskiy Alexander M.9ORCID,Diaz Ariel10,Phaneuf Denis11,De Belder Mark A.12,Ma Yi-tong13,Guzman Luis A.14,Khouri Michel1,Sionis Alessandro15,Hausenloy Derek J.1617181920,Doerr Rolf21,Selvanayagam Joseph B.22,Maggioni Aldo Pietro23ORCID,Hochman Judith S.3ORCID,Maron David J.24

Affiliation:

1. Duke University Medical Center, Durham, NC (R.D.L., M.K.).

2. Duke Clinical Research Institute, Durham, NC (K.P.A., S.R.S., F.W.R.).

3. NYU Grossman School of Medicine, New York (H.R.R., J.S.H.).

4. Icahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York (G.W.S.).

5. Wayne State University/Central Michigan University, Detroit (I.L.P.).

6. Northwick Park Hospital–Royal Brompton Hospital, London, UK (A.E.).

7. Hospital Universitario La Paz, IdiPaz, CIBER-CV, Madrid, Spain (J.L.L.-S.).

8. Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil (P.S.F.).

9. E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Moscow, Russia (A.M.C.).

10. CIUSSS-MCQ, University of Montreal, Campus Mauricie, Trois-Rivieres, Canada (A.D.).

11. Hôpital Pierre-Le Gardeur, Quebec, Canada (D.P.).

12. Barts Health NHS Trust, London, UK (M.A.D.).

13. First Affiliated Hospital of Xinjiang Medical University, Urumqi, China (Y.-t.M.).

14. DAMIC Medical Institute, Cordoba, Argentina (L.A.G.).

15. Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIB–Sant Pau, CIBER-CV, Universitat Autònoma de Barcelona, Spain (A.S.).

16. The Hatter Cardiovascular Institute, Institute of Cardiovascular Sciences, University College London, UK (D.J.H.).

17. Cardiovascular & Metabolic Disorders Program, Duke–National University of Singapore Medical School (D.J.H.).

18. National Heart Research Institute Singapore, National Heart Centre (D.J.H.).

19. Yong Loo Lin School of Medicine, National University Singapore (D.J.H.).

20. Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan (D.J.H.).

21. Praxisklinik Herz und Gefaesse, Dresden, Germany (R.D.).

22. Flinders Medical Centre, Adelaide, Australia (J.B.S.).

23. ANMCO Research Center, Florence, Italy (A.P.M.).

24. Department of Medicine, Stanford University School of Medicine, CA (D.J.M.).

Abstract

Background: Whether an initial invasive strategy in patients with stable ischemic heart disease and at least moderate ischemia improves outcomes in the setting of a history of heart failure (HF) or left ventricular dysfunction (LVD) when ejection fraction is ≥35% but <45% is unknown. Methods: Among 5179 participants randomized into ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), all of whom had left ventricular ejection fraction (LVEF) ≥35%, we compared cardiovascular outcomes by treatment strategy in participants with a history of HF/LVD at baseline versus those without HF/LVD. Median follow-up was 3.2 years. Results: There were 398 (7.7%) participants with HF/LVD at baseline, of whom 177 had HF/LVEF >45%, 28 HF/LVEF 35% to 45%, and 193 LVEF 35% to 45% but no history of HF. HF/LVD was associated with more comorbidities at baseline, particularly previous myocardial infarction, stroke, and hypertension. Compared with patients without HF/LVD, participants with HF/LVD were more likely to experience a primary outcome composite of cardiovascular death, nonfatal myocardial infarction, or hospitalization for unstable angina, HF, or resuscitated cardiac arrest (4-year cumulative incidence rate, 22.7% versus 13.8%; cardiovascular death or myocardial infarction, 19.7% versus 12.3%; and all-cause death or HF, 15.0% versus 6.9%). Participants with HF/LVD randomized to the invasive versus conservative strategy had a lower rate of the primary outcome (17.2% versus 29.3%; difference in 4-year event rate, −12.1% [95% CI, −22.6 to −1.6%]), whereas those without HF/LVD did not (13.0% versus 14.6%; difference in 4-year event rate, −1.6% [95% CI, −3.8% to 0.7%]; P interaction = 0.055). A similar differential effect was seen for the primary outcome, all-cause mortality, and cardiovascular mortality when invasive versus conservative strategy–associated outcomes were analyzed with LVEF as a continuous variable for patients with and without previous HF. Conclusions: ISCHEMIA participants with stable ischemic heart disease and at least moderate ischemia with a history of HF or LVD were at increased risk for the primary outcome. In the small, high-risk subgroup with HF and LVEF 35% to 45%, an initial invasive approach was associated with better event-free survival. This result should be considered hypothesis-generating. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01471522.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3